Funding to continue work in the Molecular Pathogenesis of Male Reproductive Disorders
Press Release , June 26, 2017

CBNS researcher Dr Mike Whittaker and Dr Betty Exintaris (Monash Institute of Pharmaceutical Sciences) along with Professor Gail Risbridger and Dr Stuart Ellem (Monash University), have been successful in securing funding from the International Research Training Group (IRTG) between Monash University and Justus-Liebig University (JLU), Germany.

The German Research Foundation first established the funding for the IRTG in 2013, with the primary objective of training a new generation of researchers to tackle a critical global health issue: men’s reproductive health. This program, called Molecular Pathogenesis of Male Reproductive Disorders will now be extended for a further 4.5 years, until 2022.

The renewal funding will provide more than $6.5 million AUD with CBNS researcher Dr Mike Whittaker and Dr Betty Exintaris (Monash Institute of Pharmaceutical Sciences) along with Professor Gail Risbridger and Dr Stuart Ellem (Monash University), have been successful in securing funding from the International Research Training Group (IRTG) between Monash University and Justus-Liebig University (JLU) Germany, along with 11 tuition and living stipend scholarships.
This new project will investigate a novel target for the treatment of the lower urinary tract symptoms associated with a benign enlargement or growth of the prostate gland:benign prostate hyperplasia (BPH). While BPH is not usually life-threatening, its symptoms caused by constriction of the urethra can have a major effect on quality of life. The JLU Giessen partners on the project are experts on smooth muscle contractility in the male reproductive system, including cGMP signaling and the influence of androgens on the prostate.

This project will also fund 2 PhD tuition and living stipends, as well as the opportunity to spend significant research time at the partner university and co-branded PhDs.